Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • 1368 Preclinical development o...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
1368 Preclinical development of an agonistic anti-TNFR2 antibody (BI-1910) for cancer immunotherapy

1368 Preclinical development of an agonistic anti-TNFR2 antibody (BI-1910) for cancer immunotherapy

Bibliographic Details
Main Authors: Monika Semmrich, Linda Mårtensson, Ingrid Teige, Björn Frendeus, Mathilda Kovacek, Petra Holmkvist, Carolin Svensson, Therese Blidberg, Andres McAllister, Marie Borggren, Ingrid Karlsson, Mark Cragg, Mimoza Bodén, Kirstie Cleary, Osman Dadas, Benjamin Duell, Jan Anders Nilsson, Stephen Beers, Sean Lim, Johan E Wallin
Format: Article
Language:English
Published: BMJ Publishing Group 2023-11-01
Series:Journal for ImmunoTherapy of Cancer
  • Holdings
  • Description
  • Similar Items
  • Staff View

Similar Items

  • 725 Pre-clinical development of TNFR2 ligand-blocking BI-1808 for cancer immunotherapy
    by: Monika Semmrich, et al.
    Published: (2020-11-01)
  • 757 Phase 1/2a clinical trial of BI-1808, a monoclonal antibody to tumor necrosis factor receptor 2 (TNFR2) as single agent and in combination with pembrolizumab
    by: Michael Chisamore, et al.
    Published: (2023-11-01)
  • Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject ‘cold’ tumors
    by: Laetitia Fend, et al.
    Published: (2022-01-01)
  • Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy–Focus on FcγRIIB
    by: Ingrid Teige, et al.
    Published: (2019-03-01)
  • 594 BT-001, an oncolytic vaccinia virus armed with a Treg-depleting human recombinant anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment
    by: Laetitia Fend, et al.
    Published: (2020-11-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs